Abstract
Biomedical research and clinical trials for curative HIV interventions are advancing rapidly. Understanding the potential impact of an HIV cure on transmission dynamics is key for its successful implementation at the population level. Using a mathematical model calibrated to the HIV epidemic among men who have sex with men (MSM) in the Netherlands as a case study, we tested the common hypothesis that an effective cure will contribute to HIV control and help end the epidemic. Guided by the target product profile (TPP) for an HIV cure, we evaluated the impact of two cure scenarios: (i) HIV remission, which entails suppression of the virus in the absence of ongoing antiretroviral treatment (ART) but carries a risk of viral rebound, and (ii) HIV eradication, which aims for complete removal of the virus. We found that either sustained HIV remission (with no risk of rebound) or HIV eradication could consistently reduce cumulative HIV incidence among MSM in the Netherlands by up to 50% for optimum TPP within eight years, relative to the baseline scenario without a cure. In contrast, transient HIV remission with a risk of rebound may drastically increase cumulative HIV incidence and disrupt the progress made toward HIV control under the current standard of care and prevention. These findings underscore the importance of the characteristics of curative HIV interventions in maximizing their benefits for public health and highlight the need to align HIV cure research with public health objectives to end the HIV epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors gratefully acknowledge funding from Aidsfonds Netherlands (grant number P53902) and the Netherlands Organization for Scientific Research (NWO), SPIRAL project KICH2.V4P.AF23.00.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee (20-546/C) of University Medical Center Utrecht gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study will be available upon publication.
